Earnings Preview — 2831 total
Entrada Therapeutics heads into its May 8 earnings event carrying a story that goes well beyond the financials — topline data from its lead DMD programme drops on May 7, the day before the print. The company announced…
NRDS enters its Q1 2026 earnings today having shed roughly one-fifth of its short interest over the past month — a notable de-risking of the bear trade before the print. Short interest has fallen 19% over 30 days to…
Fluence Energy enters its Q2 FY2026 earnings call on May 7 with short sellers firmly positioned — and options traders piling in alongside them just as the stock stages a sharp recovery. Short interest has climbed to…
GLOBALFOUNDRIES heads into its Q1 2026 earnings report with a wall of analyst upgrades at its back and a stock that has surged 65% over the past month. The analyst activity is the headline story. In the 72 hours before…
Dutch Bros heads into its Q1 2026 earnings tonight with short sellers meaningfully committed — yet a resurgent stock and bullish analyst consensus make this one of the more contested setups in the restaurant…
RDW heads into its Q1 2026 earnings today with a defining overhang: a dominant insider has spent the past month systematically reducing its stake. AE Industrial Partners — formerly RDW's controlling shareholder and a…
Amplitude reports Q1 2026 results on May 8 with analyst consensus firmly bullish but valuations well below targets — a gap the print will either begin to close or widen further. The bull case centres on execution.…
Faraday Future Intelligent Electric heads into its May 8 earnings print with one of the most heavily shorted float profiles in its sector — and the borrow market is nearly tapped out. Short sellers control 35.2% of the…
Surrozen reported Q1 2026 results after the close on May 6, delivering a headline EPS miss that would ordinarily send a clinical-stage biotech sharply lower — yet the setup heading into the print was notably bullish,…
CS Disco enters its Q1 2026 earnings report today with the stock deep in the red — down nearly 20% on the session and 17% over the past week to $3.72. The numbers themselves just printed ahead of the close: Q1 adjusted…
Sight Sciences reports Q1 2026 earnings today with the stock up 22% over the past month — but analysts still deeply divided on whether that rally reflects genuine fundamental recovery or gets ahead of the evidence. The…
ZVIA heads into its Q1 2026 print with a consistent insider selling pattern that runs counter to analyst optimism. The insider story is the sharpest signal in the data. CEO Amy Taylor sold shares across three separate…
HLLY heads into its Q1 2026 print with the stock already under real pressure, raising the stakes for what management says about the back half. The stock fell 13% on May 6 alone, closing at $2.87 — down 10% on the week…
Alpha Teknova delivered a cleaner-than-expected Q1 and held its full-year sales guidance, yet the short-selling backdrop heading into the May 8 call remains more charged than the headline beat might suggest. The…
TaskUs reports Q1 2026 results on May 8 having shed more than half its short interest over the past month — a striking retreat from bears that now frames the earnings setup. Short interest in TASK has fallen roughly…
Tenaya Therapeutics heads into today's earnings print with one of the most elevated short scores in the biotech universe — yet the stock has been climbing. The short side is deeply embedded here. Short interest runs at…
TCRX arrives at tomorrow's Q1 2026 results having shed more than half its short interest in a month — a sharp retreat that stands out for a micro-cap biotech carrying this much clinical risk. The short-selling pullback…
HNST heads into its Q1 2026 earnings report today with short sellers retreating — quietly signalling more caution about pressing the bear trade than the headline numbers might suggest. Short interest has fallen sharply…
SRTA heads into its May 7 earnings report with a notable insider selling cluster — and a 28% one-month stock rally that gave executives plenty of reason to act. On April 24, four insiders sold shares in a coordinated…
Context Therapeutics heads into its May 8 earnings call having already reported Q1 numbers — and the initial read is a beat. The EPS surprise is the headline. Q1 EPS came in at $(0.09), topping the $(0.12) estimate.…
